[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ejaculatory-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ejaculatory-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,71,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642693","water-vapor-thermal-therapy-versus-ejaculation-sparing-bipolar-transurethral-enucleation-for-benign-prostatic-hyperplasia-100642693",false,"NCT07648888","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","REZ-ESBTUEP","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) 15 mL\u002Fs or less with voided volume 150 mL or more.\n* Post-void residual urine volume 250 mL or less.\n* Failed, intolerant, or unwilling to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Recurrent urinary retention or suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.","MALE","50 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective comparative study will evaluate Water Vapor Thermal Therapy (WVTT\u002FRezum) versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate (ES-B-TUEP) in sexually active men with symptomatic benign prostatic hyperplasia.\n\nEligible patients will have moderate-to-severe lower urinary tract symptoms, preserved antegrade ejaculation at baseline, and will be candidates for procedural treatment after failure, intolerance, or unwillingness to continue medical therapy. This is not a randomized study. Treatment selection will be based on shared decision-making between the patient and the treating surgeon after standardized counseling about both procedures.\n\nThe study will compare ejaculatory function, urinary symptom improvement, urinary flow, post-void residual urine, erectile function, perioperative outcomes, complications, catheterization duration, hospital stay, medication restart, and retreatment or reintervention during follow-up. The primary outcome will be the change in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form Function domain score from baseline to 12 months.",[27,28,29],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms","Ejaculatory Dysfunction",[31,32,33],"Water Vapor Thermal Therapy","Ejaculation-Sparing","MSHQ-EjD-SF","RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2026-06-08",{"date":42,"type":21},"2027-12",{"name":44,"class":45},"Beni-Suef University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":69,"locationsCount":46},"100467736","emsella-chair-vs-sham-for-male-sexual-dysfunction-100467736","NCT05370651","Emsella Chair vs Sham for Male Sexual Dysfunction","A Single-Blind, Randomized Study of the BTL Emsella Chair Versus Sham for the Treatment of Male Sexual Dysfunction","Emsella_EJD","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about adverse events and other clinically important information.\n2. Men ≥ 18 years of age.\n3. Sexually active within the past 12 weeks and plan to be sexually active during the next 12 weeks.\n\n5\\. Self-reported ejaculatory dysfunction symptoms present \\>3 months 6. Self-reported failed conservative care of behavioral modifications and\u002For oral medications.\n\n7\\. Subject agrees not to start any new treatment for erectile dysfunction or ejaculatory dysfunction during the treatment and follow-up periods.\n\nExclusion Criteria:\n\n1. Botox® use in bladder or pelvic floor muscles in the past year\n2. Subject weighs greater than 330 pounds, due to weight limits of the Emsella Chair.\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure of tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, thigh, or buttocks.\n5. Major metal implants such as: metal plates, screws, joint replacements, implanted cardiac pacemakers, drug pumps, neurostimulators, electronic implants, defibrillators, and metal implants in the pelvic area. Patients with other metal implants will be evaluated by the investigator for inclusion in the study.\n6. Previous or current penile prosthesis.\n7. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n8. Active urethral diverticula\n9. Known history of urethral stricture disease\n10. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n11. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation.\n12. Subject has used the BTL EMSELLA device previously\n13. Subject has sexual dysfunction of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy, neurogenic bladder etc.\n14. Current use of neuromodulation therapy, including Interstim and percutaneous tibial nerve stimulation (PTNS), for bladder symptoms within 3 months of screening visit (if past sacral\u002Fpudendal implant, must be explanted)\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    * Note for the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.","18 Years",{"count":57,"type":21},117,[24],"We will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue on to phase 2, which is a sham controlled, randomized blinded study. Participants in phase 2 will be randomized to receive either active treatment or sham. Potentially a total of 117 participants for both phases will be enrolled.\n\nThe purpose of this study is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of sexual dysfunction, specifically erectile dysfunction (EjD) in men.",[61,29],"Male Sexual Dysfunction",[61],"2025-12-05",{"date":65,"type":38},"2025-12-11",{"date":67,"type":38},"2022-12-14",{"date":42,"type":21},{"name":70,"class":45},"Corewell Health East",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100592137","clinical-outcomes-and-ejaculatory-function-in-bpo-patients-treated-with-silodosin-100592137","NCT06989515","Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin","Does Anejaculation Reflect Better Clinical Outcomes in BPO Patients Receiving Silodosin?","Inclusion Criteria:\n\n* Male patients aged 40 years or older\n* Diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO)\n* Initiating silodosin 8 mg\u002Fday therapy for the first time\n* Able to complete IPSS and IIEF-5 questionnaires\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History of prior treatment with silodosin or other α-blockers in the last 3 months\n* Known neurogenic bladder or history of neurological disease affecting voiding\n* History of prostate surgery or pelvic radiation\n* Diagnosed prostate or bladder malignancy\n* Use of medications affecting sexual function (e.g., PDE5 inhibitors) within the last month\n* Severe cardiovascular, hepatic, or renal comorbidities\n* Cognitive impairment preventing informed consent or questionnaire completion","40 Years",{"count":80,"type":21},100,"OBSERVATIONAL","This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.",[84,85,29,86,87],"Benign Prostate Obstruction (BPO)","Lower Urinary Tract Symptom","Anejaculation","Silodosin",[87,29,89,28,90],"Benign Prostatic Obstruction","Alpha-blocker Side Effects","NOT_YET_RECRUITING","2025-06-04",{"date":94,"type":38},"2025-06-05",{"date":96,"type":21},"2025-06-15",{"date":98,"type":21},"2026-06-12",{"name":100,"class":45},"Marmara University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":109,"minAge":55,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":81,"phases":4,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":46},"100562615","ejaculatory-and-orgasmic-dysfunction-registry-100562615","NCT06605469","Ejaculatory and Orgasmic Dysfunction Registry","Ejaculatory and Orgasmic Dysfunction Registry (Climax Registry)","Inclusion Criteria:\n\n* Men being treated for either ejaculatory and\u002For orgasmic dysfunction\n* For partners, inclusion is being a sexual partner of a man with ejaculatory and\u002For orgasmic dysfunction who is receiving treatment\n\nExclusion Criteria:\n\n* None",true,"ALL",{"count":111,"type":21},500,"3 Years","The goal of this observational study is to evaluate the safety and efficacy of various therapies used to treat ejaculatory and\u002For orgasmic dysfunctions in men. The objective is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and\u002For orgasmic dysfunction.\n\nParticipants will submit questionnaires about their diagnosis and treatment efficacy and multiple time intervals.",[29,115,116,117,86,118,119],"Premature Ejaculation","Delayed Ejaculation","Anorgasmia","Dysejaculation","Dysorgasmia",[121,122,123,124,125,126,127],"ejaculatory dysfunction","premature ejaculation","delayed ejaculation","anorgasmia","anejaculation","dysejaculation","dysorgasmia","2025-02-12",{"date":130,"type":38},"2025-02-14",{"date":132,"type":38},"2024-05-30",{"date":134,"type":21},"2029-05-31",{"name":136,"class":45},"Charitable Union for the Research and Education of Peyronie's Disease"]